Milestone Pharmaceuticals Inc. Payments to Acquire Short-term Investments
Milestone Pharmaceuticals Inc. (MIST) reported Payments to Acquire Short-term Investments of $79.97 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2026-08-12
- Milestone Pharmaceuticals Inc. payments to acquire short-term investments for the quarter ending 2026-06-30 was -$18.00K, a 140.00% decline year-over-year.
- Milestone Pharmaceuticals Inc. payments to acquire short-term investments for the quarter ending 2026-03-31 was $79.98M, a 9020.30% increase year-over-year.
- Milestone Pharmaceuticals Inc. payments to acquire short-term investments for the quarter ending 2025-12-31 was $47.01M, a 236.56% increase year-over-year.
- Milestone Pharmaceuticals Inc. payments to acquire short-term investments for the quarter ending 2025-09-30 was $34.98M, a 17.55% increase year-over-year.
- Milestone Pharmaceuticals Inc. payments to acquire short-term investments for fiscal 2025 was $82.92M, a 26.98% decline from fiscal 2024.
- Milestone Pharmaceuticals Inc. payments to acquire short-term investments for fiscal 2024 was $113.55M, a 17.19% decline from fiscal 2023.
- Milestone Pharmaceuticals Inc. payments to acquire short-term investments for fiscal 2023 was $137.13M, a 59.73% increase from fiscal 2022.
- Milestone Pharmaceuticals Inc. payments to acquire short-term investments for fiscal 2022 was $85.85M, a 472.35% increase from fiscal 2021.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$18.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $79.97M 10-Q · filed 2026-08-12 | $126.98M derived: sum of 3 quarters · filed 2026-08-12 | $161.96M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $79.98M 10-Q · filed 2026-05-13 | $127.00M derived: sum of 2 quarters · filed 2026-05-13 | $161.98M derived: sum of 3 quarters · filed 2026-05-13 | $162.03M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $47.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $82.00M derived: sum of 2 quarters · filed 2026-03-20 | $82.04M derived: sum of 3 quarters · filed 2026-08-12 | $82.92M 10-K · filed 2026-03-20 |
| 2025-09-30 | $34.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $35.03M derived: sum of 2 quarters · filed 2026-08-12 | $35.90M 10-Q · filed 2025-11-12 | $49.87M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $45.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $922.00K 10-Q · filed 2026-08-12 | $14.89M derived: sum of 3 quarters · filed 2026-08-12 | $44.65M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $877.00K 10-Q · filed 2026-05-13 | $14.85M derived: sum of 2 quarters · filed 2026-05-13 | $44.61M derived: sum of 3 quarters · filed 2026-05-13 | $61.92M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $13.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $43.73M derived: sum of 2 quarters · filed 2026-03-20 | $61.04M derived: sum of 3 quarters · filed 2026-03-20 | $113.55M 10-K · filed 2026-03-20 |
| 2024-09-30 | $29.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $47.07M derived: sum of 2 quarters · filed 2025-11-12 | $99.58M 10-Q · filed 2025-11-12 | $140.88M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $17.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $69.83M 10-Q · filed 2025-08-12 | $111.12M derived: sum of 3 quarters · filed 2025-08-12 | $136.96M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $52.51M 10-Q · filed 2025-05-14 | $93.81M derived: sum of 2 quarters · filed 2025-05-14 | $119.65M derived: sum of 3 quarters · filed 2025-05-14 | $174.65M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $41.29M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $67.13M derived: sum of 2 quarters · filed 2025-03-13 | $122.13M derived: sum of 3 quarters · filed 2025-03-13 | $137.13M 10-K · filed 2025-03-13 |
| 2023-09-30 | $25.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $80.84M derived: sum of 2 quarters · filed 2024-11-12 | $95.84M 10-Q · filed 2024-11-12 | $118.74M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $55.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $70.00M 10-Q · filed 2024-08-08 | $92.91M derived: sum of 3 quarters · filed 2024-08-08 | $132.85M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $15.00M 10-Q · filed 2024-05-13 | $37.91M derived: sum of 2 quarters · filed 2024-05-13 | $77.85M derived: sum of 3 quarters · filed 2024-05-13 | $92.85M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $22.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $62.85M derived: sum of 2 quarters · filed 2024-03-21 | $77.85M derived: sum of 3 quarters · filed 2024-03-21 | $85.85M 10-K · filed 2024-03-21 |
| 2022-09-30 | $39.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $54.95M derived: sum of 2 quarters · filed 2023-11-13 | $62.95M 10-Q · filed 2023-11-13 | $62.95M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $15.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $23.00M 10-Q · filed 2023-08-10 | $23.00M derived: sum of 3 quarters · filed 2023-08-10 | |
| 2022-03-31 | $8.00M 10-Q · filed 2023-05-11 | $8.00M derived: sum of 2 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $15.00M 10-K · filed 2023-03-29 | ||
| 2021-09-30 | $15.00M 10-Q · filed 2022-11-10 | |||
| 2020-12-31 | $30.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $58.00M derived: sum of 2 quarters · filed 2022-03-24 | $90.00M 10-K · filed 2022-03-24 | |
| 2020-09-30 | $28.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $60.00M 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $32.00M 10-Q · filed 2021-08-11 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $0.00 derived: sum of 2 quarters · filed 2021-03-29 | $35.00M 10-K · filed 2021-03-29 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $35.00M 10-Q · filed 2020-11-13 | ||
| 2019-06-30 | $35.00M 10-Q · filed 2020-08-12 | |||
| 2018-12-31 | -$5.97M derived: 10-K/A 12 month − 10-Q 9 month · filed 2020-10-23 | $3.03M 10-K/A · filed 2020-10-23 | ||
| 2018-09-30 | $9.00M 10-Q · filed 2019-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |